Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)
Diagnosis of amnestic Mild Cognitive Impairment (aMCI) or early Alzheimer’s
Currently resides in the greater New York City or Rockland County areas
Has at least a high school diploma/12 years of education
Does not have a history of brain tumor, MRI evidence of serious neurological disorders such as epilepsy, ALS, Parkinson’s disease, MS, Tourette syndrome, or history of significant cardiovascular or cerebrovascular disease.
About the Study:
The TRAP-AD study is investigating an experimental treatment device for amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer’s disease in a randomized clinical trial of 8 weeks of transcranial
photobiomodulation (tPBM) or sham (placebo) treatment. The t-PBM treatment stimulates
certain parts of the brain that are thought to be affected in memory impairment and may improve cognition in adults with aMCI and early Alzheimer’s.
The TRAP-AD study will test whether an experimental treatment device that uses near-infrared light therapy will lead to improvement in cognition in adults with amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer’s.
What is Involved:
The tPBM device uses near-infrared light to stimulate areas of the brain near the forehead; it is a non-pharmacologic investigational treatment. Participants will first complete an assessment of medical history and memory to verify eligibility, undergo medical imaging procedures, and will then be randomized to either t-PBM or sham (placebo) treatment for 8 weeks (3 sessions per week, approximately 30-minute visit time per session). Following treatment, cognitive symptoms will be assessed two additional times to detect any improvement.